650nm Low-level Red-light for Myopia Control and Prevention in Children

NCT ID: NCT05786586

Last Updated: 2024-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

572 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-26

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter randomized controlled trial, evaluating the efficacy and safety of 650nm low-level red-light irradiation for myopia control and prevention in children. Participants included children(aged 6 to 12 years, spherical equivalent error of 0.5D or below) who are already myopic at recruitment, and those who are of Emmetropia or low hyperopia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicenter randomized controlled trial will be conducted in three hospitals: Beijing Tongren Hospital, and another two subcenters. The whole study will last for five years.The investigators will perform data analysis at 6 months follow-up, one-year follow-up, two-year follow-up, three-year follow-up, four-year follow-up and the end of the study. The intervention measure used will be 650 nm low-level red-light. This kind of intervention will be integrated into a headworn device. This device could be used for treatment of myopia or amblyopia, and is safe for the eyes and has been verified by the Chinese market supervision and administration department.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

650 nm low-level red-light, plus single vision spectacle lenses

Children in the treatment group are expected to receive 6 minutes irradiation of 650 nm low-level red-light daily, divided into two times a day, each lasting for 3 minutes. Single vision spectacle lenses are allowed for myopic children.

Group Type EXPERIMENTAL

650 nm low-level red-light

Intervention Type DEVICE

650 nm low-level red-light is a kind of laser, concentrated into a beam, to repeatedly irradiate the retina

Control

Single vision spectacle lenses are allowed for myopic children. No intervention was given.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

650 nm low-level red-light

650 nm low-level red-light is a kind of laser, concentrated into a beam, to repeatedly irradiate the retina

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 6 to 12 years
* The cycloplegic spherical equivalent error (SER) is -6D to 1D (\> -6D, ≤1D) in both eyes
* Astigmatism of 2.5 D or less (≤2.5D)
* Willing to participate in the study and sign the informed consent form

Exclusion Criteria

* Using other myopia interventions or stopped using them for less than three months, including but not limited to atropine eye drops or orthokeratology lens
* With anisometropia (difference in sphere between two eyes was 1.5D or greater), strabismus, or amblyopia
* With refractive media opacification (keratopathy, lens opacity, etc.)
* Allergy to cycloplegia drugs
Minimum Eligible Age

6 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Children's Hospital

OTHER

Sponsor Role collaborator

Children's Hospital of The Capital Institute of Pediatrics

OTHER

Sponsor Role collaborator

Beijing Tongren Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ying Jie, MD

Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ying Jie

Role: PRINCIPAL_INVESTIGATOR

Beijing Tongren Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Tongren Hospital

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TongrenJY2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Red Light Childhood Myopia Proof-of-concept
NCT06771258 NOT_YET_RECRUITING NA